3/15/23, The Indicator (8:55)
Link: https://www.npr.org/2023/03/15/1163748730/new-drugs-cheaper-drugs-why-not-both
Summary: The Inflation Reduction Act allows Medicare to negotiate the price of some drugs. What if this happened at a larger scale? The dismal answer would be “less incentive for pharma to innovate.” Yes, there is no such thing as a free lunch, but what about a cheaper lunch? The Indicator offers an optimistic view and our classroom exercise analyzes these policy ideas that may offer a solution to this “knotty” dilemma between prices and new drugs.
audioecon 